India · Delayed Price · Currency is INR Navin Fluorine International Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and profitability grew strongly in Q4 and FY26, with robust performance across all segments and improved margins. Strategic CapEx projects and a strong order book support double-digit growth outlook for FY27, while risk management and capital discipline remain priorities.
-
Q3 and nine-month FY 2026 saw robust revenue and profit growth, with all business segments delivering strong results and margin expansion. Capacity additions, new project ramp-ups, and disciplined cost control underpin a positive outlook, with ongoing CapEx and policy support fueling future growth.
-
Q2 FY 2026 saw 46% YoY revenue growth and a 129% jump in EBITDA, with all business segments performing strongly. Major CapEx projects in HFC and Specialty Chemicals are set to drive future growth, while EBITDA margin guidance for FY 2026 is raised to 28%-30%.
-
Q1 FY26 delivered 39% revenue growth and 129% net profit growth, with all divisions performing strongly and margins expanding to 28.5%. Strategic projects, robust order book, and expanded CapEx frame support a positive outlook, despite ongoing pricing pressures in agchem.
Fiscal Year 2025
-
Record annual and quarterly revenues were achieved, with strong EBITDA margin expansion and robust growth across all segments. Strategic partnerships in advanced materials and high-purity chemicals, along with disciplined CapEx and margin guidance, position the business for continued growth.
-
Q3 FY25 saw 21% revenue growth and a 95% jump in operating EBITDA, with margins reaching 24.3%. Key projects like the Dahej agro-specialty plant and R32 expansion are on track, and strong order books support a positive outlook for specialty chemicals and CDMO.
-
Q2 FY25 revenue grew 10% year-on-year, led by HPP and CDMO, while Specialty Chemicals saw a 15% decline but is expected to recover in H2. Strong order visibility and ongoing capacity expansions support a positive outlook, with net debt to equity at 0.39.
-
Revenue grew 7% YoY in Q1 FY25, led by HPP, while specialty and CDMO segments faced headwinds from global agro destocking and deferred demand. Multiple CapEx projects are on track, with margin improvement and stronger H2 FY25 outlook expected.